Germany’s Merck KGaA specified the targets of its ongoing restructuring programme on Tuesday, saying it eyes 300 million euros ($385 million) in annual cost cuts at its prescription drugs unit by 2014. It said in a statement it would incur one-off costs of about 600 million euros related to the programme between this year and 2014.
